The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Frankenfield Christopher James since 2026.
This trader's CIK number is 1988344.
At the time of last reporting, Frankenfield Christopher James was the Chief Financial Officer of Xilio Therapeutics, Inc.. (stock ticker symbol XLO).
Also see all insider trading activities at Xilio Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | XLO | 0 | $0 | 21,090 | $13,560 | 58,125 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-01-02 | XLO | Sale | 7,030 | .64 | 4,520 |
| 2026-01-01 | XLO | Option Ex | 19,375 | .00 | 0 |
| 2026-01-02 | XLO | Sale | 7,030 | .64 | 4,520 |
| 2026-01-01 | XLO | Option Ex | 19,375 | .00 | 0 |
| 2026-01-02 | XLO | Sale | 7,030 | .64 | 4,520 |
| 2026-01-01 | XLO | Option Ex | 19,375 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Frankenfield Christopher James (Chief Financial Officer of Xilio Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.